PET imaging of tumours with a 64Cu labeled macrobicyclic cage amine ligand tethered to Tyr3-octreotate

• Published in: Dalton transactions : an international journal of inorganic chemistry 2014-01, Vol.43 (3), p.1386-1396
• Main Authors: Paterson, Brett M, Roselt, Peter, Denoyer, Delphine, Cullinane, Carleen, Binns, David, Noonan, Wayne, Jeffery, Charmaine M, Price, Roger I, White, Jonathan M, Hicks, Rodney J, Donnelly, Paul S
• Format: Article
• Language: English
• Subjects: Amines - chemistry; Animals; Cell Line, Tumor; Coordination Complexes - chemical synthesis; Coordination Complexes - chemistry; Copper Radioisotopes - chemistry; Crystallography, X-Ray; Isotope Labeling; Ligands; Mice; Mice, Inbred BALB C; Molecular Conformation; Neoplasms - diagnostic imaging; Peptides, Cyclic - chemistry; Positron-Emission Tomography; Radiography; Radiopharmaceuticals - chemistry; Radiopharmaceuticals - metabolism; Tissue Distribution
• ISSN: 1477-9234
• DOI: 10.1039/c3dt52647j

The use of copper radioisotopes in cancer diagnosis and radionuclide therapy is possible using chelators that are capable of binding Cu(II) with sufficient stability in vivo to provide high tumour-to-background contrast. Here we report the design and synthesis of a new bifunctional chelator, 5-(8-methyl-3,6,10,13,16,19-hexaaza-bicyclo[6.6.6]icosan-1-ylamino)-5-oxopentanoic acid (MeCOSar), that forms copper complexes of exceptional stability by virtue of a cage amine (sarcophagine) ligand and a new conjugate referred to as SarTATE, obtained by the conjugation of MeCOSar to the tumour-targeting peptide Tyr(3)-octreotate. Radiolabeling of SarTATE with (64)Cu(II), a radioisotope suitable for positron emission tomography (PET), was fast (~20 min), easily performed at room temperature and consistently resulted in high radiochemical purity (>99%). In vitro and in vivo evaluation of (64)CuSarTATE demonstrated its high selectivity for tumour cells expressing somatostatin receptor 2 (sstr2). Biodistribution and PET imaging comparisons were made between (64)CuSarTATE and (64)Cu-labeled DOTA-Tyr(3)-octreotate ((64)CuDOTATATE). Both radiopharmaceuticals showed excellent uptake in sstr2-positive tumours at 2 h post-injection. While tumour uptake of (64)CuDOTATATE decreased significantly at 24 h, (64)CuSarTATE activity was retained, improving contrast at later time points. (64)CuSarTATE accumulated less than (64)CuDOTATATE in the non-target organs, liver and lungs. The uptake of (64)CuSarTATE in the kidneys was high at 2 h but showed significant clearance by 24 h. The new chemistry and pre-clinical evaluation presented here demonstrates that MeCOSar is a promising bifunctional chelator for Tyr(3)-octreotate that could be applied to a combined imaging and therapeutic regimen using a combination of (64)Cu- and (67)CuSarTATE complexes, owing to improved tumour-to-non-target organ ratios compared to (64)CuDOTATATE at longer time points.